Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer — a phase II trial

Bernardi, Daniele; Talamini, Renato; Zanetti, Martina; Simonelli, Cecilia; Vaccher, Emanuela; Spina, Michele; Tirelli, Umberto

doi:10.1038/sj.pcan.4500685

Cited by 8 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ahmad (2004) 91 Commentary/overview Anonymous (2002) 92 Wrong patient group Anonymous (2004) 93 Commentary/overview Anonymous (2001) 94 Background Anonymous (2000) 95 Background Arcenas (2003) 96 Not an RCT Arlen (2002) 97 Commentary/overview Autorino (2003) 98 Commentary/overview Aventis Pharma (2004) 99 Background Aventis Pharma (2004) 100 Background Aventis Pharma (2004) 101 Background Aventis Pharma (2004) 16 Background Beedassy (1999) 102 Commentary/overview Beer (2000) 103 Not an RCT Beer (2003) 104 Background Beer (2002) 105 Background Beer (2004) 106 Background Beer (2001) 107 Background Beitz (1999) 108 Commentary/overview Bernardi (2004) 109 Not an RCT Berry (2003) 110 Not an RCT Bloomfield (1997) 111 Not an RCT Bloomfield (1997) 112 Not an RCT Bosnjak (2003) 113 Background Bracarda (2002) 114 Not an RCT Brandes (2000) 115 Not an RCT Bucher (1997) 63 Background Cancer Research UK (2004) 117 Commentary/overview Carducci (1999) 118 Commentary/overview Centre for Reviews and Dissemination (2001) 23 Background Chamberlain (1997) 11 Background Chang (2005) 119 Background Chatta (2004) 120 Commentary/overview Clarke (2004) 121 Background Coleman (2004) 10 Background Collette (2004) 122 Commentary/overview …”

Section: Study Details Reason For Exclusionmentioning

confidence: 99%

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer

Collins¹,

Fenwick²,

Trowman³

et al. 2007

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, now part of the National Institute for HealthResearch (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as ro...

show abstract

Section: Study Details Reason For Exclusionmentioning

confidence: 99%

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer

Collins¹,

Fenwick²,

Trowman³

et al. 2007

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…Mitoxantrone is a synthetic anthracenedione-based anticancer drug developed as a doxorubicin analogue with decreased cardiotoxicity [1]. Mitoxantrone has a broad spectrum of antimor activity, being used in the treatment of advanced breast and prostate cancer, leukemia, lymphoma and multiple sclerosis [2][3][4][5]. The advantage of the mitoxantrone use relies in a reduced cardiotoxicity of anthracyclines and retaining or improving their antitumor activity.…”

mentioning

confidence: 99%

ESR Spectroscopy Insight on the Anticancer Drug Mitoxantrone Location in Membrane Mimetic Systems

2020

Rev.Chim.

View full text Add to dashboard Cite

The location of mitoxantrone molecule in micelles formed by bile salts (sodium taurocholate (NaTC) and sodium taurodeoxycholate (NaTDC)) and sodium dodecyl sulfate (SDS) have been investigated by electron spin resonance (ESR) spectroscopy, using three doxylstearic acid probes (5-, 12- and 16-doxylstearic acid abbreviated as 5-DSA, 12-DSA and 16-DSA). The analysis of ESR parameters of these spin probes evidenced slower dynamics induced by mitoxantrone that vary in the following order: 12-DSA > 5-DSA > 16-DSA for both bile salts micelles and 5-DSA > 12-DSA > 16-DSA for SDS micelles. The ESR parameters are slightly sensitive to variation of pH. These results indicate that the spin probes target different regions in these aggregates. Keywords: mitoxantrone, bile salts micelles, SDS micelles, ESR spectroscopy

show abstract

Assessing outcomes in prostate cancer clinical trials

Gignac

Morris

Heller

et al. 2008

Cancer

View full text Add to dashboard Cite

BACKGROUND. Because of the osseous distribution of prostate cancer metastases, progression is more readily identified than response in prostate cancer clinical trials. As a result, there is an increased focus on progression-free survival (PFS) as a phase 2 endpoint. PFS, however, is vulnerable to inter-study design variability. The authors sought to identify and quantify this variability and the resultant error in PFS across prostate cancer clinical trials. METHODS.The authors reviewed phase 2 clinical trials of cytotoxic agents in castration-resistant metastatic prostate cancer over 5 years to evaluate the policies determining extent of disease and the definitions of disease progression. A simulation model was created to define the degree of error in estimating PFS in 3 hypothetical cohorts (median PFS of 12, 24, and 36 weeks) when the frequency of outcome assessments varies. RESULTS.Imaging policies for trial entry were heterogeneous, as were the type, timing, and indications for outcome assessments. In the simulation, error in the reported PFS varied according to the interval between assessments. The difference between the detected and the true PFS could vary as much as 6.4 weeks per cycle, strictly resulting from the variability of assessment schedules tested. CONCLUSIONS.Outcome assessment policies are highly variable in phase 2 studies of castration-resistant prostate cancer patients, despite published guidelines designed to standardize authentication of disease progression. The estimated error in PFS can exceed 6 weeks per cycle, exclusively because of variations in the assessment schedules. Comparisons of PFS times from different studies must be made with circumspection.

show abstract

Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer — a phase II trial

Cited by 8 publications

References 26 publications

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer

ESR Spectroscopy Insight on the Anticancer Drug Mitoxantrone Location in Membrane Mimetic Systems

Assessing outcomes in prostate cancer clinical trials

Contact Info

Product

Resources

About